Find relevant U.S. clinical, commercial and ecosystem pathways for your product.
Weekly edition: Oct 9, 2026AI-prepared; human review pendingSources checked: Oct 9, 2026
In this edition
3 signals for your next decision
01
Upcoming2027 applications open; deadline December 1, 2026
MedTech Innovator 2027 offers a competitive U.S. partner route
What changed
MedTech Innovator’s five-month 2027 program accepts worldwide medical-device, diagnostic and digital-health applicants targeting the U.S., connecting selected companies with strategic and clinical, regulatory and reimbursement experts.
Why it matters
Japanese founders should articulate a specific U.S. use case and partner need before applying.
Consider next
Prepare a commercialization plan, confirm leadership capacity for participation and apply by December 1; an information session is listed for October 27.
Sources & context1 source
Relevant to
Early- and mid-stage device, diagnostic and regulated digital-health founders targeting the U.S.
Limits to keep in mind
The application opening date and precise deadline time were not published in the retrieved page. The October 27 session is at 12 p.m. Eastern / 9 a.m. Pacific. Selection is competitive; introductions do not guarantee commercial agreements.
Source date: Not publishedEvent / deadline: Dec 1, 2026
OngoingSeptember launch; current selective application route
Mayo Clinic Platform adds a multiyear AI development pathway
What changed
Mayo Clinic Platform announced a selective multiyear Accelerate pathway with 12 initial AI companies. Its current page describes up to two years of data-environment access, advisors and technical support.
Why it matters
Japanese regulated-AI founders can assess whether the available de-identified data supports their evidence question.
Consider next
Prepare a data specification and evidence-gap assessment; verify population fit, access rights and contracting terms before seeking an interview.
Sources & context2 sources
Relevant to
Medical AI and diagnostic software requiring sustained model development and validation
Limits to keep in mind
The current pages display no application deadline or nationality restriction. Entry is selective and does not imply FDA authorization, Mayo clinical adoption or endorsement. This is not a guaranteed prospective-trial program.
UpcomingCohort already selected; next phase planned for mid-October
JETRO–TheraNova cohort illustrates readiness for U.S. evidence partners
What changed
JETRO’s five-company Medical Data Utilization cohort with TheraNova is scheduled to enter data generation and validation in mid-October, following research-partner preparation, contracting and IRB work where required.
Why it matters
Other Japanese founders can use this sequence to prepare focused requests to U.S. clinical partners.
Consider next
Define the study, data source, partner responsibilities, contracting and IRB needs, and the resulting regulatory or adoption milestone.
Sources & context1 source
Relevant to
Japanese device, diagnostic and regulated digital-health teams preparing U.S. evidence generation
Limits to keep in mind
This cohort is already selected and is not an open application opportunity. Phase dates are prospective as of October 9; the next phase has not been reported as begun. No PBIP role is evidenced.
Source date: Aug 10, 2026Event / deadline: Mid-October 2026 through March 2027